Enzeevum, a biosimilar to Eylea, is approved in Canada for multiple retinal conditions, expanding treatment options for ophthalmologists. Biosimilars may offer cost-effective alternatives, potentially ...

Samsung Bioepis completes full transfer of commercial rights from Biogen back to Samsung Bioepis for BYOOVIZ BYOOVIZ becomes the fourth biosimilar directly commercialized by Samsung Bioepis in Europe, ...

Growth is driven by the rapidly aging global population, rising prevalence of chronic diseases such as diabetes, and ...

North America leads the anti-angiogenic ophthalmic agent market due to high healthcare spending, advanced ophthalmic infrastructure, and widespread awareness of retinal diseases. The region’s rapid ...